XML 46 R39.htm IDEA: XBRL DOCUMENT v3.24.3
Collaboration and License Agreements and Supply Agreements - Additional Information (Details)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jun. 30, 2024
USD ($)
May 31, 2024
USD ($)
Apr. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
$ / shares
shares
Nov. 30, 2023
USD ($)
Installment
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
PerformanceObligation
Program
Apr. 30, 2022
USD ($)
Sep. 30, 2024
USD ($)
$ / shares
shares
Sep. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
GoodsAndServices
$ / shares
shares
Sep. 30, 2023
USD ($)
Dec. 31, 2023
USD ($)
$ / shares
shares
Dec. 31, 2022
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Accounts receivable, reserve for credit losses                 $ 0   $ 0   $ 0  
Common stock, shares issued | shares                 82,395,350   82,395,350   61,009,829  
Common stock value issued                 $ 82,000   $ 82,000   $ 61,000  
Common stock value per share | $ / shares                 $ 0.001   $ 0.001   $ 0.001  
Total transaction price                     $ 50,400,000      
Nonrefundable, non-creditable upfront payment                     50,000,000      
Revenue                 $ 8,520,000 $ 16,924,000 $ 47,234,000 $ 40,010,000    
Vaxcyte, Inc.                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
First installment milestone payment received         $ 50,000,000                  
Number of installments | Installment         2                  
Additional milestone payment received   $ 25,000,000                        
Additional milestone payment                         $ 60,000,000  
Blackstone Life Sciences                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Upfront payment received           $ 140,000,000                
2015 License Agreement | Blackstone Life Sciences | Royalty                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Upfront payment received           $ 140,000,000                
Revenue interest percentage           4.00%         4.00%      
Supply Agreement | Vaxcyte, Inc.                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Reimbursements expenses accruals                 9,400,000   $ 9,400,000   6,900,000  
Reimbursements expenses                 2,800,000 2,800,000 7,000,000 5,600,000    
Astellas License and Collaboration Agreement                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Deferred revenue                 35,100,000   35,100,000   69,000,000  
Number of target programs | Program             3              
Upfront payment received                     90,000,000      
Transaction price             $ 90,000,000              
Estimated service period             4 years              
Recognition of up front payment             $ 89,100,000              
Upfront payment revenue not recognized                     25,000,000      
Nonrefundable, non-creditable upfront payment receivable                           $ 90,000,000
Number of performance obligations | PerformanceObligation             4              
Maximum amount eligible to receive for development, regulatory and commercial milestones for each product candidate                 422,500,000   422,500,000      
Revenue                 7,661,000 9,988,000 43,798,000 23,593,000    
Astellas License and Collaboration Agreement | Ongoing Performance Related to Unsatisfied Performance Obligations                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Revenue $ 17,800,000               5,095,000 5,612,000 33,915,000 11,423,000    
Astellas License and Collaboration Agreement | Future Services on Collaboration Joint Steering Committee ("JSC")                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Recognition of up front payment             $ 900,000              
Tasly License Agreement                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Revenue                 32,000 $ 5,072,000 1,007,000 $ 5,072,000    
Maximum potential payments related to development regulatory commercialization contingent payments and milestones               $ 350,000,000            
Initial licensing payment due               25,000,000            
Initial licensing payment in escrow               $ 15,000,000            
Revenue recognized from contingent payment                         5,000,000  
Income tax charge related to contingent payment                         500,000  
Contingent payment recognized as deferred revenue                         5,000,000  
Withholding tax on deferred revenue                         $ 500,000  
Ipsen Agreement                            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                            
Deferred revenue                 50,400,000   50,400,000      
Milestone payment received       $ 7,000,000                    
Upfront license fee     $ 50,000,000                      
Common stock, shares issued | shares       4,827,373                    
Common stock value issued       $ 25,000,000         400,000   $ 400,000      
Fair market value of common stock issued     24,600,000                      
Common stock premium     $ 400,000                      
Common stock value per share | $ / shares       $ 5.18                    
Additional purchase of Common Stock       $ 10,000,000                    
Percentage of VWAP premium       0.17                    
Payment related to development and regulatory milestone       $ 447,000,000                    
Payments related to sales milestone       $ 360,000,000                    
Number of goods and services | GoodsAndServices                     3      
Revenue                 $ 166,000   $ 261,000